The company, established in 2016 and later restructured as a private limited entity in 2018, specializes in manufacturing APIs, advanced intermediates, and finished dosage forms. With robust relationships in the pharmaceutical industry, it has built a strong customer base of over 50 clients and achieved an annual turnover exceeding 200 crore. The company operates extensive facilities capable of scaling from lab-scale development to bulk production, supporting its global expansion strategy. Committed to ethical practices and social responsibility, the company aims to make healthcare affordable and accessible worldwide, with export markets across Asia, Latin America, and Africa.

This globally operating pharmaceutical company focuses on developing and manufacturing a broad range of affordable medications. They specialize in both prescription and over-the-counter drugs, including oncology treatments, antibacterials, injectables (both specialty and large volume), ophthalmic products, dermatological preparations, and veterinary pharmaceuticals. Their product portfolio also includes unique niche drugs and orphan products, showcasing their commitment to addressing diverse medical needs. The company boasts state-of-the-art manufacturing facilities located across several regions, adhering to strict quality standards recognized by international regulatory bodies like the WHO GMP, US FDA, and MCC. Their extensive global reach spans over 45 countries in Asia, Africa, Latin America, CIS, Europe, Australia, and the Pacific Ocean. The company's focus on research and development, coupled with its global manufacturing capabilities and commitment to quality, positions them as a key player in the international pharmaceutical market.

This CTD dossier owner and manufacturer focuses on providing high-quality oncology drugs to over 20 countries worldwide. With more than two decades of experience, they specialize in manufacturing sterile oncology dosage forms, including liquid vials, lyophilized formulations, and complex NDDS-based products. Their product portfolio includes over 35 products targeting various solid tumors and hematological malignancies, with a commitment to palliative care formulations as well. They prioritize research and development, particularly in advanced lyophilized, liposomal, and nanoparticle-based drug delivery systems. Their manufacturing facilities adhere to strict GMP certifications, ensuring product quality and safety. Key therapy areas include oncology, with a focus on solid tumors and hematological malignancies. Principal dosage forms include liquid vials, lyophilized formulations, and complex NDDS (New Drug Delivery Systems) based products. The company emphasizes partnerships with academia, healthcare institutions, and the local community to drive research and development efforts.